CO2Laser Moxibustion for Knee Osteoarthritis: Study Protocol for A Multicenter, Double-blind, Randomized Controlled Trial

被引:6
作者
Guo, Meng-hu [1 ]
Zhao, Ling [1 ]
Wu, Fan [1 ]
Du, Jiong [2 ]
Ding, Chen-huan [3 ]
Ge, Jing-hua [4 ]
Tan, Ming T. [5 ]
Lao, Li-xing [6 ]
Shen, Xue-yong [1 ]
Cheng, Ke [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 200021, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai 200127, Peoples R China
[4] Shanghai Changning Tianshan Tradit Chinese Med Ho, Shanghai 200051, Peoples R China
[5] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA
[6] Univ Hong Kong, Sch Chinese Med, Hong Kong, Peoples R China
基金
中国国家自然科学基金;
关键词
Chinese medicine; laser moxibustion; knee osteoarthritis; pain; randomized controlled trial; NATIONAL-HEALTH; ARTHRITIS; HIP; ACUPUNCTURE; THERAPY; UPDATE; PAIN;
D O I
10.1007/s11655-019-2714-6
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background Knee osteoarthritis (OA) is a major cause of disability among the older adults. Few treatments are safe and effective. Moxibustion is commonly used in treating knee OA in Chinese medicine (CM). CO(2)Laser moxibustion device is a substitute for traditional moxibustion, which mimics the effects of traditional moxibustion. More data are needed to support its application in knee OA. Objective ObjectiveThe trial aims to assess the effect and safety of CO(2)laser moxibustion in patients with knee osteoarthritis compared with a sham control. Methods This is a protocol for a multicenter, randomized, double-blind, placebo-controlled trial. A total of 392 participants were recruited and assigned to the CO(2)laser moxibustion group and sham laser moxibustion group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China. Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point. There were 3 sessions per week for 4 weeks, and an additional 20-week follow-up. Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores at week 4. Secondary outcomes were WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment. The serum levels of cytokines involved in progress of knee OA were explored. Safety was assessed during the whole trial. Masking effectiveness was assessed by both participants and treatment providers.This is a protocol for a multicenter, randomized, double-blind, placebo-controlled trial. A total of 392 participants were recruited and assigned to the CO(2)laser moxibustion group and sham laser moxibustion group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China. Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point. There were 3 sessions per week for 4 weeks, and an additional 20-week follow-up. Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores at week 4. Secondary outcomes were WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment. The serum levels of cytokines involved in progress of knee OA were explored. Safety was assessed during the whole trial. Masking effectiveness was assessed by both participants and treatment providers. Discussion CO(2)laser moxibustion device, designed as a substitute for CM moxibustion, is easy to use and control with no choking smoke and smell, and is a plausible method for double-blind research. This study would provide rigorous evidence for the effect and safety of CO(2)laser moxibustion in treating knee OA (Trial registration No.: ISRCTN15030019).
引用
收藏
页码:568 / 576
页数:9
相关论文
共 31 条
  • [1] DEVELOPMENT OF CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS - CLASSIFICATION OF OSTEOARTHRITIS OF THE KNEE
    ALTMAN, R
    ASCH, E
    BLOCH, D
    BOLE, G
    BORENSTEIN, D
    BRANDT, K
    CHRISTY, W
    COOKE, TD
    GREENWALD, R
    HOCHBERG, M
    HOWELL, D
    KAPLAN, D
    KOOPMAN, W
    LONGLEY, S
    MANKIN, H
    MCSHANE, DJ
    MEDSGER, T
    MEENAN, R
    MIKKELSEN, W
    MOSKOWITZ, R
    MURPHY, W
    ROTHSCHILD, B
    SEGAL, M
    SOKOLOFF, L
    WOLFE, F
    [J]. ARTHRITIS AND RHEUMATISM, 1986, 29 (08): : 1039 - 1049
  • [2] [Anonymous], 1999, MMWR-MORBID MORTAL W, V50, P120
  • [3] [Anonymous], 2011, YB POP FAM PLANN SHA, P47
  • [4] [Anonymous], 1999, CRITERIA DAGNOSIS TH, P33
  • [5] OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
    Bannuru, R. R.
    Osani, M. C.
    Vaysbrot, E. E.
    Arden, N. K.
    Bennell, K.
    Bierma-Zeinstra, S. M. A.
    Kraus, V. B.
    Lohmander, L. S.
    Abbott, J. H.
    Bhandari, M.
    Blanco, F. J.
    Espinosa, R.
    Haugen, I. K.
    Lin, J.
    Mandl, L. A.
    Moilanen, E.
    Nakamura, N.
    Snyder-Mackler, L.
    Trojian, T.
    Underwood, M.
    McAlindon, T. E.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (11) : 1578 - 1589
  • [6] BELLAMY N, 1988, J RHEUMATOL, V15, P1833
  • [7] Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee - A randomized, controlled trial
    Berman, BM
    Lao, LX
    Langenberg, P
    Lee, WL
    Gilpin, AMK
    Hochberg, MC
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (12) : 901 - 910
  • [8] Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials
    Bjordal, JM
    Ljunggren, AE
    Klovning, A
    Slordal, L
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7478): : 1317 - 1320D
  • [9] Moxibustion for the treatment of osteoarthritis: a systematic review and meta-analysis
    Choi, Tae-Young
    Choi, Jiae
    Kim, Kun Hyung
    Lee, Myeong Soo
    [J]. RHEUMATOLOGY INTERNATIONAL, 2012, 32 (10) : 2969 - 2978
  • [10] Dillon CF, 2006, J RHEUMATOL, V33, P2271